The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
The acute-phase response after bisphosphonate administration
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dinarello, C. A. (1984) · Clinical Infectious Diseases · doi:10.1093/clinids/6.1.51 · Cited by 1,644
An interleukin 1 like factor stimulates bone resorption in vitro
Gowen, M., Wood, D. D., Ihrie, E. J., McGuire, M. K. B., & Russell, R. G. G. (1983) · Nature · doi:10.1038/306378a0 · Cited by 1,012
Schenk, R., Merz, W. A., Mühlbauer, R., Russell, R. G. G., & Fleisch, H. (1973) · Calcified Tissue Research · doi:10.1007/bf02547219 · Cited by 482
Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix.
Boonekamp, P. M., van der Wee-Pals, L. J. A., LENNEP, M. V., Cw, T., & Bijvoet, O. L. (1986) · PubMed · Cited by 345
TREATMENT OF PAGET'S DISEASE WITH (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (A.P.D.)
Frijlink, W. B., Bijvoet, O. M., Te Velde, J., & Heynen, G. (1979) · The Lancet · doi:10.1016/s0140-6736(79)91318-7 · Cited by 258
Douglas, D., Graham G, R., Preston, C., Prenton, M., Duckworth, T., Kanis, J., Eric Preston, F., & Stuart Woodhead, J. (1980) · The Lancet · doi:10.1016/s0140-6736(80)91496-8 · Cited by 177
Lymphocytes, macrophages and the regulation of bone remodeling
Baron, R. (1984) · Cited by 155
Apd in paget's disease of bone role of the mononuclear phagocyte system?
Bijvoet, O. L. M., Frijlink, W. B., Jie, K., van der Linden, H. C., Meijer, C. J. L. M., Mulder, H., Paassen, H. C. V., Reitsma, P. H., Velde, J. T., Vries, E. D., et al. (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780231018 · Cited by 133
Reitsma, P. H., Teitelbaum, S. L., Bijvoet, O. L. M., & Kahn, A. (1982) · Journal of Clinical Investigation · doi:10.1172/jci110704 · Cited by 120
Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate
Adámi, S., Salvagno, G. L., Guarrera, G. M., Montesanti, F., Garavelli, S., Rosini, S., & Cascio, V. L. (1986) · Calcified Tissue International · doi:10.1007/bf02555208 · Cited by 75
Self-citation
Cited by
Camacho, P. M., Petak, S. M., Binkley, N., Diab, D. L., Eldeiry, L. S., Farooki, A., Harris, S. T., Hurley, D. L., Kelly, J., Lewiecki, E. M., et al. (2020) · Endocrine Practice · doi:10.4158/gl-2020-0524suppl · Cited by 1,182
Camacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., Kleerekoper, M., Lewiecki, E. M., Miller, P. D., Narula, H. S., et al. (2016) · Endocrine Practice · doi:10.4158/ep161435.esgl · Cited by 1,140
Bisphosphonates: Mechanisms of Action
Fleisch, H. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0325 · Cited by 1,019
Bisphosphonates: mechanisms of action.
Rodan, G. A., & Fleisch, H. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118722 · Cited by 921
Bisphosphonates: from the laboratory to the clinic and back again
Russell, R. G. G., & Rogers, M. J. (1999) · Bone · doi:10.1016/s8756-3282(99)00116-7 · Cited by 840
ASAS/EULAR recommendations for the management of ankylosing spondylitis
Zochling, J., van der Heijde, D., Burgos-Vargas, R., Collantes, E., Davis, J. C., Dijkmans, B., Dougados, M., Géher, P., Inman, R. D., Khan, M. A., et al. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.041137 · Cited by 702
Fleisch, H. (1991) · Drugs · doi:10.2165/00003495-199142060-00003 · Cited by 581
Molecular Mechanisms of Action of Bisphosphonates: Current Status
Roelofs, A. J., Thompson, K., Gordon, S., & Rogers, M. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0843 · Cited by 568
Long-Term Use of Bisphosphonates in Osteoporosis
Watts, N. B., & Diab, D. L. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1947 · Cited by 542
Camacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., Kleerekoper, M., Lewiecki, E. M., Miller, P. D., Narula, H. S., et al. (2016) · Endocrine Practice · doi:10.4158/ep161435.gl · Cited by 478
Aapro, M., Abrahamsson, P. A., Body, J. J., Coleman, R. E., Colomer, R., Costa, L., Crinò, L., Dirix, L., Gnant, M., Gralow, J., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm442 · Cited by 457
Watts, N. B., Bilezikian, J. P., Camacho, P. M., Greenspan, S. L., Harris, S. T., Hodgson, S. F., Kleerekoper, M., Luckey, M. M., McClung, M. R., Pollack, R. P., et al. (2010) · Endocrine Practice · doi:10.4158/ep.16.s3.1 · Cited by 441
Frith, J. C., Mönkkönen, J., Blackburn, G. M., Russell, R. G. G., & Rogers, M. J. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.9.1358 · Cited by 437
Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound
Green, J. R., Müller, K., & Jaeggi, K. A. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090521 · Cited by 415
Bisphosphonates act on rat bone resorption through the mediation of osteoblasts.
Sahni, M., Guenther, H. L., Fleisch, H., Collin, P., & Martin, T. J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116422 · Cited by 412
Bisphosphonates: From Bench to Bedside
RUSSELL, R. G. G. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1346.041 · Cited by 410
Adverse Effects of Bisphosphonates: A Comparative Review
Adami, S., & Zamberlan, N. (1996) · Drug Safety · doi:10.2165/00002018-199614030-00003 · Cited by 377
Self-citationOsteoporosis Due to Cancer Treatment: Pathogenesis and Management
Pfeilschifter, J., & Diel, I. J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1570 · Cited by 363
Bisphosphonate-associated adverse events
Papapetrou, P. D. (2009) · Hormones · doi:10.14310/horm.2002.1226 · Cited by 312
Antitumor effects of bisphosphonates
Green, J. R. (2003) · Cancer · doi:10.1002/cncr.11128 · Cited by 311
Management of the adverse effects associated with intravenous bisphosphonates
Tanvetyanon, T., & Stiff, P. J. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj105 · Cited by 301
Rogers, M. J., Watts, D. J., & Russell, R. G. G. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971015)80:8+<1652::aid-cncr15>3.0.co;2-z · Cited by 285
The pharmacology of bisphosphonates and new insights into their mechanisms of action
Russell, R. G. G., Rogers, M. J., Frith, J. C., Luckman, S. P., Coxon, F. P., Benford, H. L., Croucher, P. I., Shipman, C., & Fleisch, H. A. (1999) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650140212 · Cited by 279
Host response modulation in the management of periodontal diseases
Salvi, G. E., & Lang, N. P. (2005) · Journal of Clinical Periodontology · doi:10.1111/j.1600-051x.2005.00785.x · Cited by 276
Characterization of and Risk Factors for the Acute-Phase Response after Zoledronic Acid
Reid, I. R., Gamble, G. D., Mesenbrink, P., Lakatos, P., & Black, D. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0597 · Cited by 257
Benford, H. L., Frith, J. C., Auriola, S., Mönkkönen, J., & Rogers, M. J. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)26392-6 · Cited by 256
Recent advances in understanding the mechanism of action of bisphosphonates
COXON, F., THOMPSON, K., & ROGERS, M. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.03.005 · Cited by 252
Sieber, P., Lardelli, P., Kraenzlin, C. A., Kraenzlin, M. E., & Meier, C. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-012-0041-1 · Cited by 49
Osteoclast recruitment in mice is stimulated by (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate.
Marshall, M. J., Holt, I., & John Davie, M. W. (1993) · Calcified Tissue International · doi:10.1007/bf00675622 · Cited by 37
Metadata
- Authors
- Adami, S., Bhalla, A. K., Dorizzi, R., Montesanti, F., Rosini, S., Salvagno, G., & Lo Cascio, V.
- Venue
- Calcified Tissue International
- Published
- 1987-12
- Volume
- 41
- Issue
- 6
- Pages
- 326-331
- ISSN
- 0171-967X (ISSN-L)
- 1432-0827
- OpenAlex
- W2024479120
- Cited by
- 357
- References
- 13
- FWCI
- 0.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.